This page shows what was measured, who it was measured in, and what that does not settle.
What Cisplatin does in the body
Advanced testicular cancer ( 1.1 )
From the FDA-approved label: The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.
Why people take it. Advanced testicular cancer ( 1.1 )
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · Q20Q21Q62J · read 2026-08-29
Its recorded molecular formula is Cl2H6N2Pt, weighing 300.05.
US prescribing information · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · read 2026-08-30
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 69 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105
✗ The study did not show it
Who was studied
NCT02194738
How many people
8300
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-free survival (PFS)
✗ The study did not show it
Who was studied
NCT04322890
How many people
6000
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Event Free Survival (R1: MAT therapy)
✗ The study did not show it
Who was studied
NCT01704716
How many people
3300
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
✗ The study did not show it
Who was studied
NCT00002823
How many people
3300
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-Free Survival Per BICR
✗ The study did not show it
Who was studied
NCT02477826
How many people
2747
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Breast cancer event-free survival (BC-EFS)
✗ The study did not show it
Who was studied
NCT05929768
How many people
2400
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Ototoxic effects may be more severe and detrimental in pediatric patients receiving cisplatin for injection, particularly in patients less than 5 years of age.”
US prescribing information · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · read 2026-08-30
On older people, the label states: “For the treatment of metastatic testicular tumors or advanced bladder cancer, clinical studies of cisplatin for injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”
US prescribing information · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on human data from published literature, cisplatin for injection can cause fetal harm when administered to pregnant women.”
US prescribing information · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Limited data from published literature report the presence of cisplatin in human milk in low amounts.”
US prescribing information · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4, S6.
No source is stored against this line.
What is in the pack
Sold as injectable, injection, solution, injection, injection, powder, lyophilized, for solution, given by the injection, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
25 products list this as an active ingredient in the United States drug directory. 25 of them contain it and nothing else.
FDA National Drug Code directory · 63323-103 · read 2026-08-29
They are sold as injection, injection, powder, lyophilized, for solution, injection, solution and powder, taken intravenous.
FDA National Drug Code directory · 63323-103 · read 2026-08-29
The regulator's established pharmacologic class for it is platinum-based drug [epc] and platinum-containing compounds [ext].
FDA National Drug Code directory · 63323-103 · read 2026-08-29
12 published labels name it as an active ingredient. 12 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 8d170f6f-37d7-41ce-aae2-33307a6ef3ae · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 8d170f6f-37d7-41ce-aae2-33307a6ef3ae · read 2026-08-29
6 marketed supplement labels list this ingredient, classed as botanical, mineral and other combinations.
Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
Cisplatin is intravenous at 3 DOSAGE FORMS AND STRENGTHS Cisplatin for injection, USP: single-dose vials containing 50 mg of cisplatin as white to light yellow lyophilized powder for reconstitution., recorded as fda label in effect 2026-06-24 in the United States.
US prescribing information · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Cisplatin studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Cisplatin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
12 documents were read for this substance.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
Q20Q21Q62J
RxNorm concept
309311
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
10 approved applications cover products containing this substance. The earliest was NDA018057, approved 19781219 to HQ SPCLT PHARMA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (10)
Q2
On the Cisplatin label: indicated for what?
"Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) 1.1 Advanced Testicular Cancer Cisplatin for injection is indicated for the treatment of advanced testicular cancer. 1.2 Advanced…": indications and usage on Cisplatin's label. DailyMed label · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · 2026-06-24
Q3
2589 registered trials of Cisplatin — at which phases?
Registered studies posting no result
1940 of 2589
2589 registered studies of Cisplatin: 1485 phase2, 690 phase3, 570 phase1, 67 na, 29 na or unstated, 18 phase4, 16 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Terminated due to poor accrual."; 358 of 2589 registered studies
Show the evidence
Trial
NCT00002735
terminated; "Terminated due to poor accrual."
NCT00002772
terminated; "poor accrual"
NCT00003086
terminated; "no participants enrolled in a three year period"
NCT00003640
terminated; "low accrual"
NCT00003642
terminated; "low accrual"
NCT00003777
terminated; "PI left institution"
14 further recorded trials
NCT00003803
terminated; "low accrual"
NCT00004099
terminated; "low accrual"
NCT00004897
terminated; "Institutional Review Board requested termination - all patients deceased and no new accrual."
NCT00005047
terminated; "Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis."
NCT00005834
terminated; "poor accrual"
NCT00006123
withdrawn; "Never started"
NCT00006356
terminated; "low accrual"
NCT00006374
withdrawn; "Slow accrual"
NCT00014196
terminated; "This study was closed early due to poor accrual."
NCT00014313
terminated; "low accrual"
NCT00017173
terminated; "Terminated for poor accrual."
NCT00021112
terminated; "low accrual"
NCT00023868
terminated; "redesign"
NCT00025298
terminated; "low accrual"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Cisplatin used Cisplatin 50mg/m2 — over how long?
studies of Cisplatin used the recorded amount. ClinicalTrials.gov · 2026-09-01
11 recorded entries; human; also "Cisplatin 50mg/m2", "Cisplatin 75 mg/m^2", "Cisplatin 25mg/m^2"
Show the evidence
human
NCT01487226
Cisplatin 50mg/m2
NCT02862457
Cisplatin 75 mg/m^2
NCT03410030
Cisplatin 25mg/m^2
NCT03765918
Cisplatin 100 mg/m^2
NCT04907370
Cisplatin (80mg/m2)
NCT04907370
Cisplatin (100mg/m2)
5 more recorded rows
humanNCT06239727
Cisplatin (80 mg/m2)
humanNCT06239727
Cisplatin (100 mg/m2)
humanNCT06446726
Cisplatin 75 mg/m2
humanNCT06784765
cisplatin (10 mg/m2)
humanNCT07776340
Cisplatin (75 mg/m2)
recorded 2026-09-01 · last checked 2026-09-04
Q6
Cisplatin's half-life is 5 days — which schedules were studied?
5 days, the half-life Cisplatin's label states: "The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of 5 days or more." DailyMed label · 508496cb-3441-46b3-a4fe-e0d440e6adc6 · 2026-06-24
Show the evidence
half lifepharmacokinetics
5 days; The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of 5 days or more.
metabolismpharmacokinetics
Metabolism The chlorine atoms of cisplatin are more subject to chemical displacement reactions by nucleophiles, such as water or sulfhydryl groups, than to enzyme-catalyzed metabolism.
recorded 2026-06-24 · last checked 2026-09-04
Q7
Which running trial of Cisplatin could settle lifespan?
NCT03351842 measures Disease-Free-Survival-Rate, reading out 2024-09-01.
269 open trials; n 460; "Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%"
Show the evidence
Trial
NCT03351842
"Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%"; n 460; "Disease-Free-Survival-Rate"; 2024-09-01
NCT02460887
"The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT"; n 236; "Failure-free survival"; 2025-04
NCT02170090
"Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer"; n 789; "Disease free survival (DFS)"; 2025-12
NCT02299999
"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer"; n 1460; "Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm"; 2025-12
NCT04982237
"A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer"; n 445; "progression-free survival (PFS) assessed by blinded independent central review (BICR) per RECIST v1.1"; 2025-12-30
NCT06257017
"Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma"; n 20; "the radiational disease-free survival (rDFS)"; 2025-12-30
14 further recorded trials
NCT03036098
"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer"; n 1314; "Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study"; 2026-05-15
NCT05203913
"Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer"; n 32; "Disease-free survival"; 2026-06-15
NCT04753879
"Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer."; n 38; "Progression-free Survival (PFS) after 6 months according to RECIST 1.1 criteria."; 2026-07-01
NCT03410615
"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC"; n 129; "3 year event-free survival"; 2026-07-31
NCT06480864
"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer"; n 38; "Progression-free survival (PFS)"; 2026-08
NCT06927986
"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）"; n 380; "Progression-free survival (PFS) assessed by independent review committee (IRC)"; 2026-08-30
NCT01704716
"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)"; n 3300; "Event Free Survival (R1: MAT therapy)"; 2026-09
NCT04634877
"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)"; n 990; "Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence"; 2026-09-15
NCT02270814
"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma"; n 74; "Progression-free survival (PFS)"; 2026-09-30
NCT05870319
"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients"; n 376; "Progression-free survival (PFS)"; 2026-09-30
NCT05689671
"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma"; n 136; "Overall Survival (OS)"; 2026-10
NCT03425643
"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)"; n 797; "Event Free Survival (EFS)"; 2026-10-15
NCT04129502
"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations"; n 354; "Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1"; 2026-10-31
NCT06095141
"Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency"; n 30; "progression-free survival, PFS"; 2026-10-31
Q8
Which 605 trials of Cisplatin posted no result?
Posted no result
605 of 605 completed trials
Registrations
NCT00002461, NCT00003582, NCT00002492, NCT00002521, NCT00003118 and NCT00003400, and 599 more
Completion dates
oldest 1991-07; newest 2024-08-06
Show the evidence
Trial
NCT00002461
1991-07
NCT00003582
1996-12
NCT00002492
2000-02
NCT00002521
2000-02
NCT00003118
2000-03
NCT00003400
2000-03
14 further recorded trials
NCT00003776
2000-03
NCT00003214
2000-04
NCT00001450
2000-06
NCT00001499
2000-06
NCT00002654
2000-07
NCT00003231
2000-09
NCT00002711
2000-10
NCT00003263
2000-11
NCT00005636
2000-11
NCT00002675
2001-01
NCT00002783
2001-01
NCT00003269
2001-01
NCT00003413
2001-02
NCT00004176
2001-02
Q9
At the median, Cisplatin's trials enrolled 62 people — anything larger?
Median enrolment
62
Largest enrolment
8300
Registered trials counted
2479
Q10
What do 33423 spontaneous reports say about Cisplatin — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Cisplatin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 33423 reaction mentions were counted: nausea 4946; neutropenia 4381; febrile neutropenia 4144; vomiting 3979. FAERS via Open Targets · CHEMBL11359 · 2026-06-24
Show the evidence
nausea
4946
neutropenia
4381
febrile neutropenia
4144
vomiting
3979
anaemia
3609
thrombocytopenia
3188
4 more recorded rows
pyrexia
3117
dehydration
2241
disease progression
1979
malignant neoplasm progression
1839
recorded 2026-06-24 · last checked 2026-09-04
Q11
Which 10 reactions does Cisplatin's label not list?
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.